Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer
Public ClinicalTrials.gov record NCT01033032. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I/II Trial of Amrubicin as Second- or Third-Line Treatment for Patients With HER2-Negative Metastatic Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Doxorubicin has been an integral part of the treatment of women with breast cancer for many years. Since amrubicin may have more activity than doxorubicin, as well as less cardiotoxicity, evaluation of amrubicin in the treatment of advanced breast cancer should be a priority. In this Phase II study, the investigators propose an evaluation of single-agent amrubicin as second- or third-line treatment for women with metastatic breast cancer.
Study identification
- NCT ID
- NCT01033032
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 78 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2009 (Type not available)
- Primary completion
- Jul 2013 (Actual)
- Completion
- Oct 2014 (Actual)
- Last update posted
- May 3, 2022
2009 – 2014
United States locations
- U.S. sites
- 16
- U.S. states
- 14
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| NEA Baptist Clinic | Jonesboro | Arkansas | 72401 | — |
| Florida Cancer Specialists | Fort Myers | Florida | 33901 | — |
| Northeast Georgia Medical Center | Gainesville | Georgia | 30501 | — |
| Baptist Hospital East | Louisville | Kentucky | 40207 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40207 | — |
| Hematology Oncology Clinic, LLP | Baton Rouge | Louisiana | 70809 | — |
| Center for Cancer and Blood Disorders | Bethesda | Maryland | 20817 | — |
| National Capital Clinical Research Consortium | Bethesda | Maryland | 20817 | — |
| Grand Rapids Clinical Oncology Program | Grand Rapids | Michigan | 49503 | — |
| Nebraska Methodist Cancer Center | Omaha | Nebraska | 68114 | — |
| Portsmouth Regional Hospital | Portsmouth | New Hampshire | 03801 | — |
| Oncology Hematology Care, Inc | Cincinnati | Ohio | 45242 | — |
| Berks Hematology Oncology Associates | West Reading | Pennsylvania | 19611 | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37203 | — |
| The Center for Cancer and Blood Disorders | Fort Worth | Texas | 76104 | — |
| Peninsula Cancer Institute | Newport News | Virginia | 23601 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01033032, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 3, 2022 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01033032 live on ClinicalTrials.gov.